Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
International Journal of Clinical Oncology|February 5, 2025
Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II studyKatsuyuki Hotta, Sho Saeki, Shinya Sakata, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 2, 2021
A randomized trial of sodium alginate prevention of esophagitis in LA-NSCLC receiving chemoradiotherapy: OLCSG1401Kiichiro Ninomiya, Toshihide Yokoyama, Katsuyuki Hotta, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202Shoichi Kuyama, Nobuaki Ochi, Akihiro Bessho, et al.
BMC Plant Biology|August 11, 2023
Plant GARDEN: a portal website for cross-searching between different types of genomic and genetic resources in a wide variety of plant speciesHisako Ichihara, Manabu Yamada, Mitsuyo Kohara, et al.
Japanese Journal of Clinical Oncology|June 11, 2021
Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404Takashi Ninomiya, Naoyuki Nogami, Toshiyuki Kozuki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2024
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study)Shinji Nakamichi, Kaoru Kubota, Toshihiro Misumi, et al.
Clinical Lung Cancer|August 11, 2016
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403Naohiro Oda, Eiki Ichihara, Katsuyuki Hotta, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2015
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001Eiki Ichihara, Katsuyuki Hotta, Naoyuki Nogami, et al.
Translational Lung Cancer Research|August 25, 2021
Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR)Hibiki Udagawa, Eri Sugiyama, Toshiyuki Harada, et al.
International Journal of Cancer|January 10, 2024
Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancerAyako Morita, Eiki Ichihara, Koji Inoue, et al.
Pageof 7